The Role of Gut Microbiota on Cholesterol Metabolism in Atherosclerosis
Open accessThe DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Abstract
Hypercholesterolemia plays a causal role in the development of atherosclerosis and is one of the main risk factors for cardiovascular disease (CVD), the leading cause of death worldwide especially in developed countries. Current data show that the role of microbiota extends beyond digestion by being implicated in several metabolic and inflammatory processes linked to several diseases including CVD. Studies have reported associations between bacterial metabolites and hypercholesterolemia. However, such associations remain poorly investigated and characterized. In this review, the mechanisms of microbial derived metabolites such as primary and secondary bile acids (BAs), trimethylamine N-oxide (TMAO), and short-chain fatty acids (SCFAs) will be explored in the context of cholesterol metabolism. These metabolites play critical roles in maintaining cardiovascular health and if dysregulated can potentially contribute to CVD. They can be modulated via nutritional and pharmacological interventions such as statins, prebiotics, and probiotics. However, the mechanisms behind these interactions also remain unclear, and mechanistic insights into their impact will be provided. Therefore, the objectives of this paper are to present current knowledge on potential mechanisms whereby microbial metabolites regulate cholesterol homeostasis and to discuss the feasibility of modulating intestinal microbes and metabolites as a novel therapeutic for hypercholesterolemia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Regulation of the mevalonate pathway
Goldstein, J. L., & Brown, M. S. (1990) · Nature · doi:10.1038/343425a0 · Cited by 5,394 · cited 1×
“Only about one-quarter of the pooled body cholesterol is obtained from the diet mainly from animal and dairy food products, with the remaining ~75% being synthesized endogenously in the liver via the mevalonate pathway [25,26].”
BackgroundArnett, D. K., Blumenthal, R. S., Albert, M. A., Buroker, A. B., Goldberger, Z. D., Hahn, E. J., Himmelfarb, C. D., Khera, A., Lloyd-Jones, D., McEvoy, J. W., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000678 · Cited by 4,536
(2019) · doi:10.1161/cir.0000000000000677 · Cited by 4,501
Intestinal microbiota metabolism of l-carnitine, a nutrient in red meat, promotes atherosclerosis
Koeth, R. A., Wang, Z., Levison, B. S., Buffa, J. A., Org, E., Sheehy, B. T., Britt, E. B., Fu, X., Wu, Y., Li, L., et al. (2013) · Nature Medicine · doi:10.1038/nm.3145 · Cited by 4,386
Parada Venegas, D., De la Fuente, M. K., Landskron, G., González, M. J., Quera, R., Dijkstra, G., Harmsen, H. J. M., Faber, K. N., & Hermoso, M. A. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00277 · Cited by 3,820
Role of the normal gut microbiota
Jandhyala, S. M. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i29.8787 · Cited by 3,001
Influence of diet on the gut microbiome and implications for human health
Singh, R. K., Chang, H.-W., Yan, D., Lee, K. M., Ucmak, D., Wong, K., Abrouk, M., Farahnik, B., Nakamura, M., Zhu, T. H., et al. (2017) · Journal of Translational Medicine · doi:10.1186/s12967-017-1175-y · Cited by 2,599 · cited 1×
“The ability to modulate the production of these metabolites by altering the microbial composition through the diet could represent a non-pharmacological treatment for CVD [22].”
BackgroundEffects of probiotics, prebiotics, and synbiotics on human health
Markowiak, P., & Śliżewska, K. (2017) · Nutrients · doi:10.3390/nu9091021 · Cited by 2,401 · cited 2×
“Some required properties include human or animal origin, non-pathogenic, isolated from a healthy GI tract, resist bile salts and enzymes and be able to antagonize pathogens such as Clostridium difficile and Helicobacter pylori [23].”
BackgroundMechanisms and regulation of cholesterol homeostasis
Luo, J., Yang, H., & Song, B.-L. (2020) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-019-0190-7 · Cited by 1,980
The gut microbiome in atherosclerotic cardiovascular disease
Jie, Z., Xia, H., Zhong, S.-L., Feng, Q., Li, S., Liang, S., Zhong, H., Liu, Z., Gao, Y., Zhao, H., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-00900-1 · Cited by 1,638 · cited 1×
“Evidence suggests that the gut microbiome is involved in the development of CVD as studies show its association with variations in body mass index and blood lipids levels, independent of age, sex, and host genetics [9].”
BackgroundWang, Z., Roberts, A. B., Buffa, J. A., Levison, B. S., Zhu, W., Org, E., Gu, X., Huang, Y., Zamanian-Daryoush, M., Culley, M. K., et al. (2015) · Cell · doi:10.1016/j.cell.2015.11.055 · Cited by 1,317 · cited 1×
“Inhibition of gut microbiota-dependent TMAO production has been shown a promising strategy for the treatment of atherosclerosis [57].”
BackgroundA Century of Cholesterol and Coronaries: From Plaques to Genes to Statins
Goldstein, J. L., & Brown, M. S. (2015) · Cell · doi:10.1016/j.cell.2015.01.036 · Cited by 1,233
Anderson, T. J., Grégoire, J., Pearson, G. J., Barry, A. R., Couture, P., Dawes, M., Francis, G. A., Genest, J., Grover, S., Gupta, M., et al. (2016) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2016.07.510 · Cited by 1,173
Links between diet, gut microbiota composition and gut metabolism
Flint, H. J., Duncan, S. H., Scott, K. P., & Louis, P. (2015) · Proceedings of the Nutrition Society · doi:10.1017/s0029665114001463 · Cited by 1,020
Rabot, S., Membrez, M., Bruneau, A., Gérard, P., Harach, T., Moser, M., Raymond, F., Mansourian, R., & Chou, C. J. (2010) · The FASEB Journal · doi:10.1096/fj.10.164921 · Cited by 610
Bile Acid-Activated Receptors, Intestinal Microbiota, and the Treatment of Metabolic Disorders
Fiorucci, S., & Distrutti, E. (2015) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2015.09.001 · Cited by 539 · cited 7×
“The main bacteria producing SCFAs are the clostridial clusters IV and XIVa of Firmicutes including species of Eubacterium, Roseburia, Faecalibacterium, and Coprococcus [44].”
BackgroundInfluentialImpact of Lipids on Cardiovascular Health
Ference, B. A., Graham, I., Tokgozoglu, L., & Catapano, A. L. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.06.046 · Cited by 511
The TMAO-Generating Enzyme Flavin Monooxygenase 3 Is a Central Regulator of Cholesterol Balance
Warrier, M., Shih, D. M., Burrows, A. C., Ferguson, D., Gromovsky, A. D., Brown, A. L., Marshall, S., McDaniel, A., Schugar, R. C., Wang, Z., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2014.12.036 · Cited by 414 · cited 1×
“FMO3 knockdown has been hown to alter biliary excr tion, int stin l absorption and limit the production of hepatic oxysterols and cholesteryl esters in cholesterol-fed mice [66].”
BackgroundCho, C. E., Taesuwan, S., Malysheva, O. V., Bender, E., Tulchinsky, N. F., Yan, J., Sutter, J. L., & Caudill, M. A. (2017) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201600324 · Cited by 405
Trimethylamine N-oxide promotes atherosclerosis via CD36-dependent MAPK/JNK pathway
Geng, J., Yang, C., Wang, B., Zhang, X., Hu, T., Gu, Y., & Li, J. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.11.016 · Cited by 297
Mortensen, M. B., & Nordestgaard, B. G. (2020) · The Lancet · doi:10.1016/s0140-6736(20)32233-9 · Cited by 290 · cited 1×
“High levels of blood cholesterol, also known as hypercholesterolemia, is a major risk factor for the development of atherosclerosis, a chronic lipid-driven inflammatory disease of the arteries, promoting myocardial infarctions and strokes [13,14].”
BackgroundMicrobial impact on cholesterol and bile acid metabolism: current status and future prospects
Kriaa, A., Bourgin, M., Potiron, A., Mkaouar, H., Jablaoui, A., Gérard, P., Maguin, E., & Rhimi, M. (2019) · Journal of Lipid Research · doi:10.1194/jlr.r088989 · Cited by 264 · cited 13×
“(3) Subsequently, the gut microbiota plays a role on cholesterol conversion into coprostanol making it easily eliminable with defection and reducing its absorption [4].”
BackgroundMethodInfluentialTrimethylamine-N-oxide (TMAO)-induced atherosclerosis is associated with bile acid metabolism
Ding, L., Chang, M., Guo, Y., Zhang, L., Xue, C., Yanagita, T., Zhang, T., & Wang, Y. (2018) · Lipids in Health and Disease · doi:10.1186/s12944-018-0939-6 · Cited by 250 · cited 8×
“Injection of FXR has been shown to induce the expression of FMO3 and the production of TMAO in mice.”
BackgroundInfluentialA review of probiotic supplementation in healthy adults: helpful or hype?
Khalesi, S., Bellissimo, N., Vandelanotte, C., Williams, S., Stanley, D., & Irwin, C. (2019) · European Journal of Clinical Nutrition · doi:10.1038/s41430-018-0135-9 · Cited by 242
Korcz, E., Kerényi, Z., & Varga, L. (2018) · Food & Function · doi:10.1039/c8fo00118a · Cited by 222
New insights into the regulation of chylomicron production
Dash, S., Xiao, C., Morgantini, C., & Lewis, G. F. (2015) · Annual Review of Nutrition · doi:10.1146/annurev-nutr-071714-034338 · Cited by 194 · cited 1×
“In enterocytes, it is esterified to CE and packaged along with apolipoproteins and TGs into chylomicrons [38].”
BackgroundCollins, H. L., Drazul-Schrader, D., Sulpizio, A. C., Koster, P. D., Williamson, Y., Adelman, S. J., Owen, K., Sanli, T., & Bellamine, A. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.10.108 · Cited by 189
Xu, Y., Li, F., Zalzala, M., Xu, J., Gonzalez, F. J., Adorini, L., Lee, Y., Yin, L., & Zhang, Y. (2016) · Hepatology · doi:10.1002/hep.28712 · Cited by 172 · cited 7×
“ABCA1 mediates the first step of reverse cholesterol transport (RCT) (further explored in Section 1.3).”
BackgroundInfluentialSasikumar, K., Kozhummal Vaikkath, D., Devendra, L., & Nampoothiri, K. M. (2017) · Bioresource Technology · doi:10.1016/j.biortech.2017.05.075 · Cited by 169 · cited 1×
“paracasei M7 exhibited cholesterol-lowering properties [114].”
Obesity: An overview of possible role(s) of gut hormones, lipid sensing and gut microbiota
Mishra, A. K., Dubey, V., & Ghosh, A. R. (2016) · Metabolism · doi:10.1016/j.metabol.2015.10.008 · Cited by 161
Effect of Probiotics on Blood Lipid Concentrations: A Meta-Analysis of Randomized Controlled Trials
Cho, Y. A., & Kim, J. (2015) · Medicine · doi:10.1097/md.0000000000001714 · Cited by 143 · cited 6×
“Because cholesterol is insoluble in water, it is packaged with triglycerides (TGs), phospholipids, and apolipoproteins (Apo) into lipoproteins that enable their transport throughout the body.”
BackgroundInfluentialKumar, R., Grover, S., & Batish, V. K. (2012) · Probiotics and Antimicrobial Proteins · doi:10.1007/s12602-012-9101-3 · Cited by 123 · cited 1×
“(2) Another mechanism whereby probiotics reduce cholesterolemia is the incorporation of cholesterol into bacterial cellular membranes [110,111].”
BackgroundPoLA/CFPiP/PCS guidelines for the management of dyslipidaemias for family physicians 2016
Banach, M., Jankowski, P., Jóźwiak, J., Cybulska, B., Windak, A., Guzik, T., Mamcarz, A., Broncel, M., & Tomasik, T. (2017) · Archives of Medical Science · doi:10.5114/aoms.2017.64712 · Cited by 86 · cited 1×
“It is important to note that nonpharmacological management should, as much as possible, accompany lipid-lowering therapy as it maximizes a patient’s outcome [16].”
Background
Cited by
Agolino, G., Pino, A., Vaccalluzzo, A., Cristofolini, M., Solieri, L., Caggia, C., & Randazzo, C. L. (2024) · Journal of Functional Foods · doi:10.1016/j.jff.2024.106357 · Cited by 99
Metadata
- Authors
- Vourakis, M., Mayer, G., & Rousseau, G.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2021-07-28
- Volume
- 22
- Issue
- 15
- Pages
- 8074
- ISSN
- 1422-0067 (ISSN-L)
- OpenAlex
- W3185521202
- Cited by
- 217
- References
- 33
- FWCI
- 8.79
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.